40th Annual J.P. Morgan Healthcare Conference

Hanmi Pharmaceutical Co., Ltd.

Se Chang Kwon

President & CEO

Forward-Looking Statements

This presentation contains forward-looking statements with respect to future financial condition, results of operations and businesses of Hanmi Pharmaceutical Company. By their nature, forward-looking statements and forecasts involve risk and uncertainties because they relate to events and circumstances that will occur in the future. There are a number of factors that could cause actual results and developments to differ materially from those expressed in or implied by the forward-looking information and statements. These risks and uncertainties include, among other things, the loss or expiration of patents, marketing exclusivity or trade marks; exchange rate fluctuations; the risk that R&D will not yield new products that achieve commercial success; the impact of competition, price controls and price reductions; taxation risks; the risk of substantial product liability claims; the impact of any failure by third parties to supply materials or services; the risk of delay to new product launches; the difficulties of obtaining and maintaining governmental approvals for products; the risk of failure to observe ongoing regulatory oversight; the risk that new products do not perform as we expect; and the risk of environmental liabilities. Hanmi does not undertake any obligation to update or revise any forward-looking information or statements.

Who We Are

Hanmi is a leading R&D oriented company with fully integrated value chains in Korea and China



Our Businesses

Strong Strategic Alliances around the Globe

"We value our partners and our innovation"

Hanmi

Beijing Hanmi

- Sales and Marketing
- Manufacturing
- PENTAMBODY Platform (BsAb)

- 6 R&D Centers
- LAPSCOVERY Platform (Biologics)
- 3 Manufacturing sites

Bioplant
Biologics
•RNA/DNA
•Protein

Fine Chemical
APIs
•Nucleotide
•Peptide
•PEG

Paltan
Finished Product
•Oral Dosage

MERCK Genentech A Member of the Roche Group SPECTRUM PHARMACEUTICALS SANDOZ AthenaX Innovent RAPT THERAPEUTICS Allegro OPHTHALMICS, LLC APTOSE BIOSCIENCES

We Value our R&D

25%
R&D staff

15% **of sales invested in R&D**

30+ **Innovative R&D assets**

Strong focus on R&D
Over +580 experts (Ph.D. 65, MS 332)

Innovative pipeline expansion through registration engineered by 6 R&D centers in Korea & China

Sustained R&D investment

Strong commitment in R&D supported by investment
Multi-angle approach powered by strong internal R&D capacity

Powerful momentum for successful open innovation

Combine internal & external expertise for successful R&D collaboration
Focus on patient-centered R&D across multiple therapeutic areas

Hanmi Open Innovation : Focused Area

Strive to discover novel assets and cutting-edge technologies through external sources of innovation

Immuno-Oncology

- ✓ First-in-class, Novel target approach
- ✓ Synergistic effects with Hanmi

RAPT THERAPEUTICS · MERCK Innovent

New Modality

- ✓ mRNA Technology and delivery system
- ✓ Next disruptive platform technology

LCB LegoChemBio · DKU

Inflammation & Fibrosis

- ✓ First-in-class ✓ Multiple MoA
- ✓ Disease-modifying therapy
- ✓ Cardiovascular, Renal and Metabolism
- ✓ Synergistic effects with Hanmi

Rare Disease & CNS

- ✓ First-in-class ✓ Neuro-inflammation
- ✓ Co-development Collaboration

Allegro OPHTHALMICS, LLC · GC Pharma

RESEARCH UPDATE

Innovative R&D Pipeline *(Dec 2021)*

	Pre-Clinical	Phase 1	Phase 2	Phase 3 / Registration
13 Oncology	**HM97662 (EZH1/2 Dual Inhibitor)** Solid tumors / Hematology malignancies	**Belvarafenib (Pan-RAF Inhibitor)** Solid tumor (Genentech)	**Poziotinib (Pan-HER Inhibitor)** Solid tumor, NSCLC (Japan) (SPECTRUM)	**Rolontis® (Eflapegrastim)** (SPECTRUM) Neutropenia (CIN) **Launched in Korea**
	BH3120 (PD-L1/4-1BB BsAb) Solid tumor	**HM43239 (Myeloid Kinome Inhibitor)** AML (APTOSE BIOSCIENCES)	**FLX475 (CCR4 inhibitor)** (RAPT THERAPEUTICS) Gastric Cancer (MERCK)	**Poziotinib (Pan-HER Inhibitor)** NSCLC (SPECTRUM)
	BH3620 (Undisclosed BsAb) Targeted immuno-oncology	**IBI315/BH2950 (PD-1/HER2 BsAb)** Solid tumor (Innovent)		**Oraxol (Oral Paclitaxel + Encequidar)** Advanced Breast cancer (Athenex)
	HM16390 (^{LAPS}IL-2 Analog) Solid tumor	**Rolontis® (Eflapegrastim)** (SPECTRUM) Neutropenia (CIN) Same-day dosing		
8 CVRM/Fibrosis	**HM14320 (^{LAPS}Glucagon Combo)** Obesity/NASH/Diabetes	**HM15136 (^{LAPS}Glucagon Analog)** Obesity	**Efinopegdutide (^{LAPS}GLP/GCG)** NASH (MERCK)	**Efpeglenatide (^{LAPS}Exd4 Analog)** Diabetes/CVRM
	HM14220 (^{LAPS}Insulin Combo) Diabetes	**HM12460A / HM12470 (^{LAPS}Insulin)** Diabetes	**HM15211 (^{LAPS}Triple Agonist)** NASH	
	HM12480 (^{LAPS}Insulin148) Diabetes			
5 Rare Diseases	**HM15450 (^{LAPS}ASB)** Mucopolysaccharidosis	**Luminate® (Integrin inhibitor)** Retinitis Pigmentosa (Allegro)	**HM15136 (^{LAPS}Glucagon Analog)** Congenital hyperinsulinism	
			HM15912 (^{LAPS}GLP-2 Analog) Short bowel syndrome	
			Efpegsomatropin (^{LAPS}hGH) GH deficiency	
4 Others	**HM72524 (mRNA/LNP)** COVID-19 variants vaccine		**Luminate® (Integrin inhibitor)** Diabetic Macular Edema (Allegro)	
			Poseltinib (BTK Inhibitor) Autoimmune/Allergic diseases	
			Oraxol (Oral Paclitaxel + Encequidar) Angiosarcoma (Athenex)	

Oncology : Focusing on Novel Assets

Sustaining Novel cancer drug Innovation through Internal and External expertise

Programs Under Development

Poziotinib *Pan-HER inhibitor*	*HER2 Exon20 NSCLC (1L/2L)* *Registrational Studies Ongoing*	SPECTRUM
Belvarafenib *Pan-RAF inhibitor*	*Solid Tumors* (NRAS melanoma) *Phase 1b*	Genentech Roche
	Solid Tumors (BRAF Class 2/3 fusion Basket Trial) *Phase 1b*	
HM43239 *Myeloid Kinome Inhibitor*	*Acute Myeloid Leukemia* *Phase 1b*	APTOSE BIOSCIENCES
FLX475 *CCR4 antagonist*	*Solid Tumors* *Phase 2*	RAPT THERAPEUTICS MERCK
HM97662 *EZH1/2 dual inhibitor*	*Multiple Indications* *Preclinical*	*Open for partnership*
HM16390 *LAPS IL-2 Analog*	*Multiple Indications* *Preclinical*	*Open for partnership*

Under Registration

Rolontis®
LAPS- GCSF

SPECTRUM

Chemo-induced Neutropenia
Korea Launched
US BLA to be Resubmitted

Poziotinib
Pan-HER inhibitor

SPECTRUM

HER2 Exon20 NSCLC (2L)
US NDA Submitted
Fast Track Designated

Oncology：Pan-HER Inhibitor (Poziotinib)

ZENITH20
Registrational Trial

Cohort 1 (n=87)
2L+ EGFR exon20 NSCLC
Fully Enrolled

***Cohort 2** (n=87)
2L+ HER2 exon20 NSCLC
Fully Enrolled

Cohort 3 (n=70)
1L EGFR exon20 NSCLC
Fully Enrolled

Cohort 4 (n=70)
1L HER2 exon20 NSCLC
Ongoing

Cohort 1 (2L+ EGFR Exon20)



*Cohort 2 (2L+ HER2 Exon20)



US NDA submitted

Cohort 3 (1L EGFR Exon20)



Cohort 4 (1L HER2 Exon20)



Oncology : Pan-RAF inhibitor (Belvarafenib)

Promising anti-tumor activity in advanced solid cancers harboring RAS- or RAF- mutation

- Best tumor volume decrease (-68.3%) in NRAS melanoma
- Global Ph1b with NRAS melanoma sponsored by Genentech
- Global TAPISTRY basket trial with BRAF class II/III by Roche

Clinical Ph1b	2020	2021	2022
KRAS G13D CRC	KR		
BRAF V600 CRC	KR		
NRAS melanoma	KR	Global (Genentech)	
RAS-/RAF-m Basket	KR		
BRAF V600 melanoma	KR		
BRAF class II/III fusion	KR	Global (Basket) (Roche)	
BRAF V600 CRC		KR	

Best Target Percentage Change: Total*



Details of the Patients with PR

Mutation Subtype	Cancer Type	Best Target Change
NRAS Q61R	Melanoma	- 68.3 %
NRAS Q61K	Melanoma	- 65.9 %
BRAF V600E	Melanoma	- 50.8 %
NRAS Q61R	Melanoma	- 37.7 %
KRAS G13D	CRC	- 37.5 %
NRAS Q61K	Melanoma	- 35.2 %
NRAS Q61	Melanoma	- 33.7 %

*Presented at ASCO 2021 by Dr. Sang Joon Shin

Oncology：Myeloid Kinome Inhibitor (HM43239)

Comparable activity observed against resistance cell lines



Phase 1/2 Study Design: FLT3 mutated or wild-type AML



HM43239 showed encouraging activity in R/R AML patients across several key disease genotypes



- Phase 1/2 Study is actively ongoing (US/KR)
- US ODD designated for AML (Oct 2018)
- Licensed out to Aptose Biosciences (Nov 2021)

Oncology : EZH1/2 inhibitor (HM97662)

Open for partnership Hanmi

Next generation EZH1/2 dual inhibitor

- ☑ Overcoming the resistance from EZH2 selective inhibitor
- ☑ Effective tumor volume decrease at lower dose
- ☑ Enhanced EZH1 inhibition activity compared to other EZH1/2i
- ☑ Potential synergistic effects in combination

Activity of Tazemetostat and HM97662 in resistant cell



EZH1 and EZH2 inhibition activity of HM97662

Inhibition activity against EZH1/2

IC_{50} (nM)	EZH1	EZH2
HM97662 (EZH1/2i)	**16**	**2.1**
Tazemetostat (EZH2i)	188	2.8

Based on encouraging preclinical data,

First-in-Human study will be initiated in 2022

- Phase 1 IND submission is anticipated (1Q 2022)
- Phase 1 FIH study initiation in KR, AU, US (2Q 2022)
- Dose-escalation/expansion study planned (3-4Q 2022)

Bispecific Antibody Platform Technology

PENTAMBODY™ Platform Technology



- ☑ Simple and Robust Bi-specific Platform
- ☑ Enhanced Stability and Manufacturability
- ☑ Platform in-human Validation On-going (Ph1)

Programs Under Development

BH2950/IBI315 *PD-1/Her2*	*Solid Tumor* ***CN Phase 1b Ongoing***	innovent **Co-development*
BH3120 *PD-L1/4-1BB*	*Solid Tumor* ***IND-enabling***	***Open for partnership***
BH3012 *PD-L1/CD47*	*Solid & Liquid Tumor* ***Preclinical Evaluation***	***Open for partnership***
BH3737 *Trop2 Biparatopic*	*Solid Tumor* ***Candidate Selected***	***Open for partnership***
BH4503 *BsAb ADC*	*Solid Tumor* ***Research Collab.(2021 2H)***	LCB LegoChem Bio

PD-1/Her2 Phase 1a/b Clinical Study

Phase 1a:
Dose Escalation ***No DLT/MTD**

Phase 1b:
Dose Expansion



First-in-class, First-in-human
PD-1/Her2 Bispecific Ab

- Phase 1a dose escalation completed : No DLT/MTD observed
- Showed promising efficacy and safety profile in cancer patients
- Phase 1b dose expansion ongoing : PoC available by 1H 2022

Metabolic Diseases : Focusing on Novel Assets

Exploring the potential for expanding indications

To maximize the value of innovative drugs

Programs Under Development

Efpeglenatide *GLP-1*	*Diabetes/CVRM*	*Phase 3*	*Exploring Innovative Potential in CVRMs*
Efinopegdutide *GLP-1/Glucagon (Dual Agonist)*	*NASH*	*Phase 2*	MERCK
LAPS Triple Agonist ***HM15211*** *Glucagon/GIP/GLP-1*	*NASH*	*Phase 2*	*FDA Fast track* *Open for partnership*
	PBC, PSC, IPF *IND enabling study*		*PBC & PSC (FDA ODD)* *IPF (FDA ODD, 2021.05)*
LAPS Glucagon Analog ***HM15136*** *Glucagon*	*Hypoglycemia (CHI)*	*Phase 2*	*Open for partnership*
LAPS GLP-2 Analog ***HM15912*** *GLP-2*	*SBS*	*Phase 2*	*Open for partnership*

Key Highlight

Potent Liver fat Reduction

LAPS Triple Agonist
HM15211
Glucagon/GIP/GLP-1

P2b with Biopsy Confirmed NASH patients

First "Monthly" GLP-2 drug

LAPS GLP-2 Analog
HM15912
GLP-2

P2 initiation with SBS-IF patients as monotherapy

CVRM: Cardiovascular Renal and Metabolism
NASH: Nonalcoholic steatohepatitis
PBC: Primary Biliary Cholangitis
PSC: Primary Sclerosing Cholangitis
IPF: Idiopathic Pulmonary Fibrosis
CHI: Congenital Hyperinsulinism

Diabetes : New Opportunity for CVRM[1]

Phase 3 Study

AMPLITUDE-O
(CVOT)
N= 4076

AMPLITUDE-M
(MONO)
N= 406

AMPLITUDE-D
(vs Dula)
N= 908

AMPLITUDE-L
(Add on to basal insulin)
N= 370

AMPLITUDE-S
(Add-on to Met ± SU)
N= 312

CVOT : MACE
(with Number of Subjects at Risk)

Primary Endpoint



CVOT : Renal Function
(with Number of Subjects at Risk)

Secondary Endpoint



Glycemic Control : ΔHbA1c
(% vs baseline)



Outstanding cardiovascular benefits
in addition to robust glycemic control

- Successfully completed most of Phase 3 AMPLITUDE studies
- Demonstrated superiority in MACEs & renal function outcomes[2]
- Comparable glycemic control and GI safety with other GLP-1RAs
- Sustaining innovation by exploring disease modifying effect on CVRM

*[1]Notes: Cardiovascular Renal and Metabolism
*[2]Notes: Major Adverse Cardiovascular Events

NASH : LAPSGlucagon/GLP-1 Dual Agonist (Efinopegdutide)

Body Weight Change[1]



Metabolic Parameters[1]



Phase 2a Open-label Study to evaluate efficacy and safety[2]
(BMI 25 ~ 50 kg/m², Liver fat ≥10%, w/ or w/o T2DM)

Total subjects N≈130, 24 weeks



Successful repositioning upon CVRM benefits

on track to unveil the prospective value

- Achieved Double digit weight loss
- Improvement of broad metabolic profiles, risk factors for NASH
- Licensed out to Merck (Aug 2020)
- Phase 2a study in NAFLD in progress (WW including US, EU, KR)

*[1]Notes: Clinical trial No. NCT03486392
*[2]Notes: Clinical trial No. NCT04944992

NASH : LAPSGlucagon/GIP/GLP-1 Triple Agonist (HM15211)

Relative liver fat changes after 8 ~ 12 weeks HM15211 treatment (by MRI-PDFF²)



Phase 2b Study Seamless Adaptive Design (Biopsy-confirmed NASH and fibrosis F1-3, w/ or w/o T2DM)



Hepatic transcriptome, NASH/fibrosis in animal

Metabolic risk factors related to NASH/Fibrosis	HM15211 (Triple Agonist)		Semaglutide (GLP-1 Mono.)
Lipid metabolism (β-Oxidation)	☑	>	☐
Inflammation	☑	>	☐
Fibrosis	☑	>	☐

Multi-target engagement by optimized triple agonism

"The right incretin for NASH / Fibrosis"

- Liver targeting leading to distinguished performance for liver fibrosis
- Differentiated hepatic lipid metabolism, anti-inflammatory and -fibrotic potential beyond GLP-1
- FDA fast-track granted: NASH (Jul 2020)
- Phase 2 study in biopsy-proven NASH / fibrosis patients (US, KR)

LAPS Glucagon/GIP/GLP-1 Triple Agonist : in-depth approach to fibrosis & inflammation

Creating better treatment for patients suffering from Fibrosis & Inflammation

Indications Under Development / Consideration

Liver Fibrosis NASH	Phase 2 b (Ongoing indication)	FDA Fast-Track
Biliary Fibrosis PBC/PSC	IND enabling	FDA ODD
Lung Fibrosis IPF ✓	IND enabling	(May 2021) FDA ODD

NASH: Nonalcoholic steatohepatitis
PBC: Primary Biliary Cholangitis
PSC: Primary Sclerosing Cholangitis
IPF: Idiopathic Pulmonary Fibrosis
COPD: Chronic Obstructive Pulmonary Disease

Change in SpO_2 over time in IPF animal model[1,2]



- Experimentally confirmed greater mortality improvement over existing IPF drugs

*[1]Notes: Bleomycin (BLM)-induced IPF mice
*[2]Notes: Average SpO_2 (Saturation pulse O_2) in normal group was used as baseline SpO_2

Rare Diseases

The True Innovation should

Embrace patients with rare disease



Short Bowel Syndrome (SBS) (3-4 per million)	Congenital Hyperinsulinism (CHI) (20-40 per million)	Lysosomal Storage Diseases
Monthly GLP-2 Orphan Drug Designation (ODD) in US & EU (Jun. 2020)	Weekly Glucagon Orphan Drug Designation (ODD) in US & EU (Jun. 2020)	Long-acting Subcutaneous Enzyme Replacement Therapy

Congenital Hyperinsulinism : LAPS Glucagon Analog (HM15136)

Open for partnership Hanmi

Patients and Families Suffer from CHI[1]

- ☑ One out of 50,000 children is developed with CHI
- ☑ Patients with diffuse CHI live with life-long treatment
- ☑ Insufficient treatments leading to high unmet needs
- ☑ Significant burden for patients and families

Medical Unmet Needs of Existing Treatment[2]



Phase 2, MAD, open-label, PoC study[5]
(CHI patient w/ ≥ 12 years old or 2 ~ 11 years old)

Cohort "A" Adolescent and Adult (≥ 12 years old)	Cohort "C" Children (2 to 11 years old)
HM15136 0.04 mg/kg + SoC (N=3)	HM15136 0.06 mg/kg + SoC (N=3)
HM15136 0.06 mg/kg + SoC (N=3)	HM15136 0.06 mg/kg + SoC (N=3)

[Key efficacy endpoint]
Change from baseline in number/rate of hypoglycemia

Proven concept for sustained glucagon engagement

Novel option for preemptive treatment of CHI

- Differentiated MoA against existing treatment
- QoL for patients and caretakers through weekly injection & soluble formulation
- Prolonged blood glucose elevation across clinical trials
- ODD[3] granted: CHI (US, EU, and KR) / RPD[4] granted: CHI (US)
- Phase 2 study in CHI patients (US, UK, and DE)

*[1]Notes: Congenital Hyperinsulinism
*[2]Notes: HI Global Registry 2021 Annual Report . (n.d.). Retrieved from https://congenitalhi.org/wp-content/uploads/2021/10/2021-HI-Global-Registry-Report-IRB-Approved.pdf·
*[3]Notes: Orphan Drug Designation
*[4]Notes: Rare Pediatric Disease
*[5]Notes: Clinical trial No. NCT04732416

Short Bowel Syndrome : LAPSGLP-2 Analog (HM15912)

Open for partnership Hanmi

Phase 1 Study Design (SAD in Healthy volunteer)



Estimated number of treated SBS patients across major markets



Study Result[1]: Fasting citrulline level



*[1]Notes: Change from baseline
ODD= Orphan drug designation; RPD= Rare pediatric disease
IND= Investigational New Drug; CTA= Clinical Trial Application

First 'Once-a-Month' injection

Medical and Quality of Life benefit

- Potent intestinotrophic action of LAPSGLP-2 analog
- The first "Once-a-Month' treatment option
- Ready-to-inject with soluble formulation

Clinical trial Status

- ODD grant in US and EU, RPD grant in US (Jun 2020)
- Fast track granted in US and France (Sep 2021)
- Phase 2 IND/CTA granted in with monthly regimen
  (Jan 2021, US; Aug 2021, Germany; Sep 2021, France & Poland)

mRNA platform technology

Within organized internal infrastructure,
" mRNA platform successfully established "

"Diversified development strategy "
For Post pandemic

01 Organization of mRNA platform / COVID-19 vaccine development

Goal: Build Hanmi's own mRNA platform
Preparation of Vaccine COVID-19 pandemic

- ✓ **Securing proprietary mRNA vaccine platform & key starting substance**
- ✓ **Gene construct covering COVID-19 variants**
  : including δ and ο variants
- ✓ **Preparation of Hanmi vaccine candidate for COVID-19**
  : Significant neutralizing effect over current mRNA vaccine against delta variant as well as SARS-CoV-2

02 Expansion to various disease area

Goal: Confirm therapeutic potential
" Protein-based" → " mRNA-based "

- ✓ **Cancer**
  : monoclonal antibodies, modified interleukin, tumor antigen
- ✓ **Metabolic disorders & CVRM**
  : Cytokine-based drug candidate
- ✓ **Enzyme replacement therapy**
  : Focusing on Lysosomal storage disorders with high medical unmet needs and/or absence of treatment option
  (MPS III, Mucolipidosis IV, Gangliosidosis, Krabbe's disease etc.)

✓ Completed ✓ On-going

COLLABORATION

Major R&D Achievements

History of Global Collaborations with partners

"The Way to Sustain Innovation and Growth"

2009

MERCK

Amosartan

Amlodipine+Losartan

2011

Athenex

Orascovery Platform Tech

Oral Paclitaxel / Irinotecan

2012

SPECTRUM PHARMACEUTICALS

Rolontis®

Long acting GCSF

2013

SANOFI

Rovelito

Irbesartan+Atorvastatin

2015

SPECTRUM PHARMACEUTICALS

Poziotinib

Pan-HER inhibitor

2016

Genentech
A Member of the Roche Group

Belvarafenib

RAF inhibitor

2017

Innovent

Anti-PD-1/HER2 Bi-specific antibody

Targeted Immuno-Oncology

2018

MERCK

Rosuzet

Rosuvastatin +Ezetimibe

2019

RAPT THERAPEUTICS

MERCK

FLX475

CCR4 inhibitor, Immuno-Oncology

2020

MERCK

Efinopegdutide

Weekly GLP/GCG NASH

2021

APTOSE BIOSCIENCES

HM43239

Myeloid Kinome Inhibitor

Value-added Programs

- Sustained growth in Korea with core value-added products
- Launching 2~3 products annually
- Seeking partners for emerging markets

Amosartan® Family
Amlodipine + Losartan FDC**
Amlodipine + Losartan + Rosuvastatin FDC**
Amlodipine + Losartan + Chlorthalidone FDC**
Amlodipine + Losartan + Rosuvastatin + Ezetimibe FDC**

Rosuzet® MERCK
Rosuvastatin + Ezetimibe FDC**

Rovelito® SANOFI
Irbesartan + Atorvastatin FDC**

Hanmi Tams®
Tamsulosin 0.2mg, 0.4mg, ODT IMD*

Monterizine®
Montelukast + Levocetirizine FDC**

Esomezol®
Esomeprazole strontium IMD*

Amodipin®
Amlodipine Camsylate IMD*

Pidogul®
Clopidogrel napadislate IMD*

Gugutams®
Tamsulosin + Tadalafil FDC**

Naxozol®
Naproxen+ Esomeprazole strontium FDC**

Rabone D®
Raloxifene + Vit D FDC**

*IMD (Incrementally Modified Drug); **FDC (Fixed Dose Combination)

Top value-added products

(bn KRW, *Non-consolidated)



Domestic business growth

HANMI OUTLOOK

Potential news flows in 2022

- ***Rolontis®*** *The first commercial launch of a biologic with LAPS platform*
- ***Poziotinib*** *The potential first to market for HER2 Exon20 mutant NSCLC*
- ***LAPS Triple Agonist*** *Phase 2b study interim data from biopsy confirmed NASH patients*
- ***LAPS Glucagon, LAPS GLP-2 Analog*** *Phase 2 initiation for orphan diseases patients (CHI, SBS)*

PHASE 1	PHASE 2	PHASE 3	Registration
Belvarafenib	*LAPS Triple Agonist* Data Available	*Efpeglenatide*	*Rolontis® US*
Myeloid Kinome inhibitor	*Efinopegdutide*	*Oraxol*	*Poziotinib US*
PD-1/HER2 BsAb	*LAPS Glucagon* Updated		
	LAPS GLP-2 Analog Updated		

"We are committed to deliver our innovation from Science to Patients"

Thank you

Hanmi Pharmaceutical Co., Ltd.